Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.5.1.18 (
glutathione S-transferase
)
22,582
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Intestinal N-acetylglucosamine 6-O-sulfotransferase (
I-GlcNAc6ST
,
GST
-4alpha) and corneal N-acetylglucosamine 6-O-sulfotransferases (C-GlcNAc6ST,
GST
-4beta) are two highly homologous GlcNAc 6-O-sulfotransferase isozymes encoded by two intronless open reading frames that reside approximately 50 kb apart on human chromosome 16q23.1.
I-GlcNAc6ST
has been shown to catalyze 6-O-sulfation of the endothelial mucin GlyCAM-1. C-GlcNAc6ST catalyzes 6-O-sulfation of GlcNAc in keratan sulfate and null-mutations in its encoding gene cause human macular corneal dystrophy. We show here that C-GlcNAc6ST efficiently catalyzes sulfation of GlyCAM-1 when coexpressed with the latter in COS-7 cells. We have further compared expression in human of both enzymes by Northern analysis with isozyme-specific probes. While I-GlcNAc6T is expressed mostly in intestinal tissue, larger C-GlcNAc6ST transcripts are found predominantly in the brain.
...
PMID:Sulfation of endothelial mucin by corneal keratan N-acetylglucosamine 6-O-sulfotransferase (GST-4beta). 1135 40
The content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1-->3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b.
GlcNAc6ST-3
(
I-GlcNAc6ST
or
GST
-4alpha) preferred Galbeta1-->3(GlcNAcbeta1-->6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for
GlcNAc6ST-3
in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of
GlcNAc6ST-3
is down-regulated in colonic adenocarcinomas.
...
PMID:Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma. 1210 80